Terns Pharmaceuticals Files 8-K
Ticker: TERN · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1831363
Sentiment: neutral
Topics: sec-filing, financials
TL;DR
Terns Pharma filed an 8-K on 9/12 for a 9/10 event, mostly financial docs.
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on September 12, 2024, reporting an event on September 10, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Terns Pharmaceuticals is providing updated financial information or exhibits to the SEC, which could be relevant for investors monitoring the company's financial status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information about significant business changes, financial distress, or regulatory actions.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- 0001193125-24-217444 (other) — Accession Number
- 20240912 (date) — Filing Date
- 20240910 (date) — Earliest Event Date
- 001-39926 (other) — SEC File Number
- 1065 East Hillsdale Blvd., Suite 100, Foster City, CA 94404 (address) — Principal Executive Offices
- (650) 525-5535 (phone) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Terns Pharmaceuticals?
The primary purpose of this 8-K filing is to report information under 'Other Events' and 'Financial Statements and Exhibits' as of September 10, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on September 12, 2024.
What is the principal executive office address for Terns Pharmaceuticals?
The principal executive office address for Terns Pharmaceuticals is 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.
What is the SEC file number for Terns Pharmaceuticals?
The SEC file number for Terns Pharmaceuticals is 001-39926.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is September 10, 2024.
Filing Stats: 1,807 words · 7 min read · ~6 pages · Grade level 14 · Accepted 2024-09-12 06:01:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
- $10.50 — ng price of the Shares to the public is $10.50 per share, and the offering price of th
- $10.4999 — he Pre-Funded Warrants to the public is $10.4999 per share underlying each Pre-Funded Wa
- $9.87 — he Underwriting Agreement at a price of $9.87 per share and the Pre-Funded Warrants f
- $9.869906 — he Underwriting Agreement at a price of $9.869906 per share underlying each Pre-Funded Wa
- $161.9 m — from the Offering will be approximately $161.9 million, after deducting underwriting dis
Filing Documents
- d878008d8k.htm (8-K) — 39KB
- d878008dex11.htm (EX-1.1) — 270KB
- d878008dex41.htm (EX-4.1) — 57KB
- d878008dex51.htm (EX-5.1) — 13KB
- d878008dex991.htm (EX-99.1) — 10KB
- g878008dsp80.jpg (GRAPHIC) — 2KB
- g878008dsp80b.jpg (GRAPHIC) — 8KB
- g878008dsp83.jpg (GRAPHIC) — 11KB
- 0001193125-24-217444.txt ( ) — 646KB
- tern-20240910.xsd (EX-101.SCH) — 3KB
- tern-20240910_lab.xml (EX-101.LAB) — 18KB
- tern-20240910_pre.xml (EX-101.PRE) — 11KB
- d878008d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated September 10, 2024, between Terns Pharmaceuticals, Inc. and Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP. 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1). 99.1 Press Release dated September 10, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document). Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements about the Company within the meaning of the federal securities laws, including the anticipated net proceeds from the Offering, the anticipated closing of the Offering and the sufficiency of the Company's cash resources, constitute forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-look
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: September 12, 2024 By: /s/ Elona Kogan Elona Kogan Chief Legal Officer